Navigation Links
Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
Date:1/3/2008

CALGARY, Jan. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the U.S. National Cancer Institute (NCI) has filed a protocol with the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial for patients with metastatic ovarian, peritoneal or fallopian tube cancers using concurrent systemic and intraperitoneal administration of REOLYSIN(R), Oncolytics' proprietary formulation of the human reovirus. The NCI is sponsoring the trial under its Clinical Trials Agreement with Oncolytics, while Oncolytics will provide clinical supplies of REOLYSIN(R).

The trial, which is being carried out at The Ohio State University Comprehensive Cancer Center, is expected to enroll up to 70 patients with metastatic ovarian, peritoneal or fallopian tube cancers.

These cancer indications were selected after comprehensive preclinical studies carried out by the NCI indicated the reovirus can kill ovarian cancer cells.

The American Cancer Society estimates that more than 22,000 women will be diagnosed with ovarian cancer in the U.S. in 2007, and more than 15,000 will die from it.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. NCI Phase I/II systemic and intraperitoneal administr
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Caustic soda is utilized in the production of ... China takes lead in the global caustic soda market, followed ... of facilities in the USA, Germany, Brazil and Canada, is ... in terms of output and production capacities. , The global ... 3% per year in the years ahead. The APAC region ...
(Date:10/31/2014)... Following the successful launch of On ... to introduce its new product and demonstrate its potential ... Launched in September, Formedix On Demand Services is the ... automation tools. For the first time, these market-leading tools ... introducing Formations – a revolutionary new token-based payment system ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/30/2014)... 2014 The report “Fragrance Ingredients Market ... (Cosmetics & Toiletries, and Soaps & Detergents) & by ... defined and segmented the Fragrance Ingredients Market with analyses ... of value. The market has been segmented on the ... Asia-Pacific, Latin America, and Rest of the World (ROW); ...
Breaking Biology Technology:China to Dominate Caustic Soda Market Through 2018, Says Merchant Research & Consulting in Its New Study 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5
... SAN CARLOS, Calif., Jan. 7 Nuvelo, Inc.,(Nasdaq: ... stockholders of Nuvelo have approved,the issuance of Nuvelo ... 24, 2008, as amended, between Nuvelo, ARCA biopharma ... adjourn Nuvelo,s special,stockholder meeting until January 23, 2009, ...
... Jan. 7 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... announced acquisition of,Axsun Technologies, Inc. , ... lasers and optical,engines used in medical Optical Coherence Tomography ...
... Jan. 7 Cold season has settled in for ... leading cause for doctor,appointments and missed days of school ... help boost your immune system. And Immunity Enhanced Beverage ... Recently introduced by Innovative Beverage Products, Immunity Enhanced,Beverage ...
Cached Biology Technology:Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5Volcano Announces Closing of Axsun Technologies Acquisition 2Innovative Beverage Products Launches New Product Designed to Enhance the Body's Immune Defense 2
(Date:10/31/2014)... uncovered key steps involved in programmed cell death, offering ... cancers and neurodegenerative diseases. , The research teams ... to discover the three-dimensional structure of a key cell ... in how it causes cell death. Their studies were ... Proceedings of the National Academy of Sciences ...
(Date:10/31/2014)... and his team have been studying the behavior ... Austrian Alps for years. They observed that ravens ... grooming and playing. However, they also observed that ... third individual. Although in about 50 % of ... up the two affiliating ravens, intervening can be ...
(Date:10/30/2014)... help reduce or reverse soil subsidence and reduce ... Sacramento-San Joaquin River Delta by Dartmouth College researchers ... one of the first to continually measure the ... cycle through wetlands, appears in the journal by ... Worldwide, agricultural drainage of organic soils has resulted ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2
... has been selected by the New Jersey Technology Council ... Award, in recognition of the Institutes consistent success in ... will be honored by the NJTC at its annual ... Jersey City, N.J., November 15, 2007. This is a ...
... us a rich and robust assemblage,of foods, medicines, ... eliminating biological diversity at an,unprecedented rate. A ... these losses relate to one,another -- information that ... protect the remaining natural variation. Sharon Strauss, ...
... aluminium fibre combination makes them nearly immune to ... developed at Delft University of Technology, will lead ... special material (called CentrAl, an abbreviation of Central ... the development of truly energy-efficient, green aircraft. Lower ...
Cached Biology News:Stevens wins Excellence in Technology Education Award 2New Delft material concept for aircraft wings could save billions 2
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used ... against various proteins and sera that are ... carriers. The array contains spots for 19 ... Application: Determination of antibody crossreactivity and species ...
... Each kit contains sufficient materials for 1,464 array ... Membrane: 4 each , Blocker BSA ... Goat Anti-Mouse Antibody, HRP-conjugated: 10 g ... , 10% Tween-20: 2 x 10 ml ...
... gun system, 100-120 V, is used for ... This handheld device employs an adjustable helium ... biomaterial-coated gold microcarriers from the inner wall ... target cells. This system has a 2 ...
Biology Products: